Big Money Bets on Cytokinetics – Cytokinetics (NASDAQ:CYTK) Big Money Bets on Cytokinetics – What It Means for Investors

Photo of author

By Ronald Tech

Enormous financial players have taken a negative position on Cytokinetics (CYTK).

And individual investors should take note.

This came to our attention today when massive trades surfaced in the publicly available options data we monitor here at Benzinga.

It is unclear whether these are institutions or affluent individuals, but when such significant activity occurs with CYTK, it often indicates that someone is privy to nonpublic information.

So how do we discern the motives behind these investors’ actions?

Today, Benzinga’s options scanner identified 85 unusual options trades for Cytokinetics.

This is highly irregular.

The prevailing sentiment among these high-stakes traders tilts towards 62% bearish and 37% bullish.

Of all the exceptional options we unearthed, 9 are puts, amounting to $740,860, and 76 are calls, totaling $7,522,268.

Projected Price Targets

Assessing the volume and open interest in these contracts suggests that prominent players have been eyeing a price range between $36.0 and $125.0 for Cytokinetics in the past quarter.

Analyzing Volume & Open Interest

Scrutinizing the volume and open interest yields crucial insights into stock research. This data is essential for gauging liquidity and interest levels in Cytokinetics’s options at specific strike prices, within a range of $36.0 to $125.0, over the last month.

Cytokinetics Option Volume And Open Interest Over Last 30 Days

Significant Options Trades Detected:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
CYTK CALL TRADE BEARISH 01/19/24 $45.00 $1.1M 14.0K 252
CYTK CALL SWEEP BEARISH 01/19/24 $45.00 $1.0M 14.0K 502
CYTK PUT TRADE BEARISH 01/19/24 $80.00 $271.0K 725 1.0K
CYTK CALL TRADE BEARISH 01/19/24 $60.00 $157.7K 18.4K 130
CYTK CALL TRADE BEARISH 06/21/24 $40.00 $134.7K 551 475

About Cytokinetics

Cytokinetics Inc is a biotech company focused on developing treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company is working on treatments for conditions such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. These treatments are based on small molecules designed specifically to enhance muscle function and contractility. The company is developing muscle-directed investigational medicines with the potential to improve the health span of individuals enduring severe cardiovascular and neuromuscular diseases with impaired muscle function.

See also  Analysis of SEC's Recent Legal Victory in Coinbase and Binance Cases Unpacking the Implications of the SEC's Recent Legal Triumph

Present Market Standing of Cytokinetics

  • With a trading volume of 4,158,467, CYTK’s price has dropped by -0.14% to $88.12.
  • Current RSI values suggest that the stock may be overbought.
  • The next earnings report is scheduled in 54 days.

Expert Opinions on Cytokinetics

In the past month, 5 industry analysts have shared their insights on this stock, presenting an average target price of $94.0.

  • An analyst from Morgan Stanley has downgraded its rating to Equal-Weight, adjusting the price target to $90.
  • An analyst from HC Wainwright & Co. maintains a Buy rating on Cytokinetics, with a target price of $94.
  • An analyst from Needham continues to support a Buy rating on Cytokinetics with a target price of $108.
  • An analyst from Truist Securities maintains a Buy rating for Cytokinetics, targeting a price of $86.
  • An analyst from Raymond James continues to advocate an Outperform rating for Cytokinetics, with a price target of $92.

Options are a riskier asset compared to simply trading the stock, but they offer higher profit potential. Serious options traders mitigate this risk by staying informed daily, gradually entering and exiting trades, considering multiple indicators, and closely following the markets.

For the latest options trade updates on Cytokinetics, Benzinga Pro provides real-time alerts.